Literature DB >> 16782822

An initial assessment of the systemic pharmacokinetics of botulinum toxin.

Easwaran Ravichandran1, Yujing Gong, Fetweh H Al Saleem, Denise M Ancharski, Suresh G Joshi, Lance L Simpson.   

Abstract

Botulinum toxin is an extraordinarily potent molecule that has an unusually long duration of action. Despite this, there is little information available on natural mechanisms for metabolism or elimination and virtually no information on pharmacologically induced mechanisms for metabolism and elimination. Therefore, a number of experiments were performed on laboratory animals that addressed two major issues: 1) the effect of blood on the structure, function, and biologic half-life of the toxin, and 2) the effect of neutralizing antibodies on half-life and elimination of circulating toxin. In the first series of studies, the metabolic transformation of toxin was assessed by incubating it in blood for varying lengths of time. At each time point, aliquots were examined to determine the amount of toxin, the structure of toxin, the catalytic activity of toxin, and the neuromuscular blocking activity of toxin. This work demonstrated that blood did not alter any characteristic of the toxin molecule. Experiments were also done in which toxin was administered to mice and rats at doses that produced clinical poisoning. The results demonstrated that the elimination half-life for native (nonmetabolized) toxin in blood and serum was 230 to 260 min. During the second series of studies, the rate of elimination of circulating toxin was studied in the presence of antibodies directed against the carboxyl-terminal half of the toxin molecule. This work demonstrated that neutralizing antibodies 1) enhanced clearance of toxin from the circulation and 2) enhanced tissue accumulation of toxin, particularly in liver and spleen.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782822     DOI: 10.1124/jpet.106.104661

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  37 in total

1.  In Vivo Toxicity and Immunological Characterization of Detoxified Recombinant Botulinum Neurotoxin Type A.

Authors:  Easwaran Ravichandran; Pavithra Janardhanan; Kruti Patel; Stephen Riding; Shuowei Cai; Bal Ram Singh
Journal:  Pharm Res       Date:  2015-11-03       Impact factor: 4.200

2.  Substrates and controls for the quantitative detection of active botulinum neurotoxin in protease-containing samples.

Authors:  Karine Bagramyan; Bruce E Kaplan; Luisa W Cheng; Jasmin Strotmeier; Andreas Rummel; Markus Kalkum
Journal:  Anal Chem       Date:  2013-05-22       Impact factor: 6.986

3.  Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route.

Authors:  Easwaran Ravichandran; Fetweh H Al-Saleem; Denise M Ancharski; Mohammad D Elias; Ajay K Singh; Mohammad Shamim; Yujing Gong; Lance L Simpson
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

Review 4.  A review of the longevity of effect of botulinum toxin in wrinkle treatments.

Authors:  G Wright; A Lax; S B Mehta
Journal:  Br Dent J       Date:  2018-02-23       Impact factor: 1.626

5.  Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A.

Authors:  Alan R Jacobson; Michael Adler; Nicholas R Silvaggi; Karen N Allen; Genessa M Smith; Ross A Fredenburg; Ross L Stein; Jong-Beak Park; Xiaochuan Feng; Charles B Shoemaker; Sharad S Deshpande; Michael C Goodnough; Carl J Malizio; Eric A Johnson; Sabine Pellett; William H Tepp; Saul Tzipori
Journal:  Toxicon       Date:  2017-07-08       Impact factor: 3.033

6.  Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: a model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare.

Authors:  Fetweh H Al-Saleem; Zidoon Nasser; Rebecca M Olson; Linsen Cao; Lance L Simpson
Journal:  J Pharmacol Exp Ther       Date:  2011-05-17       Impact factor: 4.030

Review 7.  Proteases as therapeutics.

Authors:  Charles S Craik; Michael J Page; Edwin L Madison
Journal:  Biochem J       Date:  2011-04-01       Impact factor: 3.857

8.  Enhancing the protective immune response against botulism.

Authors:  Amanda Przedpelski; William H Tepp; Abby R Kroken; Zhuji Fu; Jung-Ja P Kim; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2013-05-13       Impact factor: 3.441

9.  Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin.

Authors:  Tsuyoshi Takahashi; Suresh G Joshi; Fetweh Al-Saleem; Denise Ancharski; Ajay Singh; Zidoon Nasser; Lance L Simpson
Journal:  Vaccine       Date:  2009-02-24       Impact factor: 3.641

10.  Antibody protection against botulinum neurotoxin intoxication in mice.

Authors:  Luisa W Cheng; Larry H Stanker; Thomas D Henderson; Jianlong Lou; James D Marks
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.